ADMA Biologics adds Eduardo Rene Salas, former EY audit partner, to board as director
ADMA Biologics appointed Eduardo Rene Salas to its Board of Directors as a Class I director, effective December 30, 2024, with a term ending at the 2026 annual meeting. Salas has financial executive and audit experience, including former CFO of Wellstat Therapeutics and a 2002 to 2019 audit partner role at Ernst & Young. The filing describes this as a board appointment with standard non-employee director compensation, including an initial grant of options to purchase 20,011 shares.
Key points
- Eduardo Rene Salas appointed to Board on December 30, 2024 as a Class I director
- Term expires at the Company's 2026 annual meeting of stockholders
- Served as CFO of Wellstat Therapeutics, LLC from 2020 to 2022
- Initial grant of options to purchase 20,011 shares of common stock upon joining the Board
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 02, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.